IP Library Granted Patent US 9,884,129
Granted Patent B2
US 9,884,129 · App. 14/589,037 · Granted Feb 6, 2018

Release of agents from cells

Inventors: Jeffrey M. Karp (Brookline, MA); Debanjan Sarkar (Williamsville, NY); Praveen Kumar Vemula (Cambridge, MA)
Assignee: The Brigham and Women's Hospital, Inc.
A61K47/48915A61K31/573A61K31/704A61K35/28A61K38/1816A61K47/6921A61K47/6935A61K47/6937C12N5/0662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,129
App. No.
14/589,037
Granted
Feb 6, 2018
Kind
B2
Abstract

A composition includes an isolated cell; at least one particle within said cell; and at least one active agent associated with the particle, wherein the active agent is capable of being released from the cell. A method includes administration of such a cell to a subject.

Claims (23)

1. A method of delivering at least one active agent to a target, the method comprising:

providing an isolated cell comprising a particle within the cell, wherein the particle is associated with at least one active agent and comprising a polymer and having a size of about 500 nm to 5 μm; and

contacting the target with the isolated cell,

wherein the at least one active agent is released from the cell independently of the particle, thereby delivering the active agent to the target.

2. The method of claim 1 , wherein the particle is formulated to release the at least one active agent into the cell in a controlled or predictable manner.

3. The method of claim 1 , wherein the particle is formulated for delayed release of the at least one active agent over a period of at least 1, 3, 5, 7, or 10 days.

4. The method of claim 1 , wherein the particle is formulated to release the at least one active agent into the extracellular environment.

5. The method of claim 1 , wherein the release of the at least one active agent does not require an external stimulus or does not require cell death.

6. The method of claim 1 wherein the at least one active agent is released by degradation/dissolution/erosion/swelling of the particle, desorption/dissociation of the at least one active agent from the particle, diffusion of the at least one active agent away from the particle, or through absorption of energy.

7. The method of claim 1 , wherein the at least one active agent is a therapeutic agent.

8. The method of claim 7 , wherein the therapeutic agent is a drug, protein, enzyme, gene, nucleic acid, RNAi, or biomolecule.

9. The method of claim 1 , wherein the at least one active agent is covalently attached to the particle.

10. The method of claim 1 , wherein the at least one active agent is noncovalently entrapped in the particle.

11. The method of claim 1 , wherein the isolated cell is a stem cell or a progenitor cell.

12. The method of claim 11 , wherein the stem cell is a mesenchymal stem cell.

13. The method of claim 1 , wherein the isolated cell is viable.

14. The method of claim 1 , wherein the target is a region within a subject.

15. The method of claim 14 , wherein contacting comprises injecting or implanting the isolated cell into the subject.

16. The method of claim 1 , wherein the method is used to treat, diagnose, or image osteoporosis, cancer, inflammatory disease, Parkinson's disease, diabetes, vascular disease, heart disease, kidney disease, liver disease, infection, sepsis, anemia, thyroid disease, blood disorders, ischemic tissues, gastrointestinal disease, skin disease, lung disease, or is used for a prophylaxis or is used as a vaccine or to promote tolerance.

17. The method of claim 15 , wherein the target is a distant site from the location of injection or implantation.

18. The method of claim 14 , wherein the method comprises extravasating of the isolated cell with the particle through an endothelial layer.

19. The method of claim 1 , wherein the isolated cell has been cryopreserved prior to the step of contacting the target with the isolated cell.

20. The method of claim 1 , wherein the polymer is poly(lactide-co-glycolide).

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 14, 2022
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061758/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: KARP, JEFFREY M.; SARKAR, DEBANJAN; VEMULA, PRAVEEN KUMAR
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 035585/0886 →
Continuity (4)
Division 13501475
Provisional Application 61251801 · Oct 15, 2009
Provisional Application 61387242 · Sep 28, 2010
Related Publication 20150125540A1 · May 7, 2015